

June 1, 2000

Dockets Management Branch (HFA-305)
Food and Drug Administration
5630 Fishers Lane, Room. 1061
Rockville, MD 20852
email: FDADockets@oc.fda.gov

**Re: Notice of Participation of Kaiser Permanente in FDA Regulation of
OTC Drug Products Hearing – Docket No. 00N-1256**

To Whom It May Concern:

By this letter, Kaiser Permanente notices its request to participate in the Section 15 hearing on FDA regulation of OTC drug products on June 28 and 29. If at all possible, we would appreciate being scheduled for June 28.

I will be representing Kaiser Permanente at the hearing. The relevant details are:

Representative:	Anthony Barrueta, Counsel, Government Relations
Address:	One Kaiser Plaza Oakland, California 94612
Telephone:	510-271-6835
Affiliation:	Kaiser Foundation Health Plan, Inc. and The Permanente Medical Group, Inc.
Sponsor:	Kaiser Foundation Health Plan, Inc.

The presentation will deal primarily with marketplace and economic issues relating to Rx-to-OTC switches as they relate to prescription drug benefits and costs. It will include information collected by Kaiser Permanente's California Division about the frequency of adverse events experienced with less-sedating prescription antihistamines. It will suggest a role for health plans and PBMs in collecting data that can support the FDA's efforts in this area. It will suggest reference to international experiences in considering OTC switch citizen petitions. I expect the presentation to take no more than 8-10 minutes.

Please do not hesitate to contact me with any questions you may have.

Sincerely,

/s/

Anthony Barrueta
Counsel

00N-1256

APE 51

Kaiser Foundation Health Plan, Inc.